drugset / Trial / NCT03396393

Exploratory Study of DHA in Systemic Lupus Erythematosus Patients

NCT03396393

Phase 2 Unknown 120 enrolled Kunming Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of the study is to assess the efficacy of DHA in patients with SLE.

Timeline

Start
2018-03
Primary completion
2021-12
Completion
2022-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ARTENIMOL Small molecule 40 mg Oral
Subject ARTENIMOL Small molecule 80 mg Oral
Subject ARTENIMOL Small molecule 120 mg Oral